Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Alternative names
Publications (10 of 49) Show all publications
Wihl, J., Hagberg, O., Aljabery, F., Gårdmark, T., Hosseini, A., Jahnson, S., . . . Liedberg, F. (2025). Lower MeDiC score is associated with non-referral to multidisciplinary team meeting discussion in bladder cancer patients: a nationwide and population-based study. Acta Oncologica, 64, 616-622
Open this publication in new window or tab >>Lower MeDiC score is associated with non-referral to multidisciplinary team meeting discussion in bladder cancer patients: a nationwide and population-based study
Show others...
2025 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 64, p. 616-622Article in journal (Refereed) Published
Abstract [en]

Background and purpose: The Measure of Case-Discussion Complexity (MeDiC) tool was created to gauge case complexity at multidisciplinary team meetings (MDTM) for case selection and prioritization. We aimed to assess applicability and association with MeDiC score and non-compliance with national guide-line-recommendations for MDTM referral in a bladder cancer setting.

Material and methods: A modified MeDiC scoring system was applied in 8955 subjects with localized (T1-T4N0M0) or metastasized disease as per the Bladder Cancer Data Base Sweden (BladderBaSe) 2.0. Association between MeDiC score and not being discussed at MDTM was investigated by multivariable logistic regression, and further explored in relation to calendar time period, healthcare region, age at diagnosis and hospital volume.

Results and interpretation: Median total MeDiC score was lower in individuals not being discussed at an MDTM (7.0 Inter Quartile Range [IQR] 6.0–9.0) compared to those who were (8.0 IQR 6.0–10.0). Adjusted odds ratio for not being discussed at an MDTM was 2.1 (95% confidence interval [CI] 1.8–2.4) for a MeDiC score in the lower quartile, as compared to the highest quartile, with higher estimates when perform-ing stratified analyses in later calendar years and in specific healthcare regions. Our data indicate that the MeDiC score is applicable in bladder cancer patients, and we identified an association between lower MeDiC score and not being discussed at an MDTM.

Place, publisher, year, edition, pages
MJS Publishing, 2025
Keywords
Bladder cancer, complexity factors, guidelines, multidisciplinary team meeting, scoring system, treatment recommendation
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-239468 (URN)10.2340/1651-226X.2025.42756 (DOI)40325792 (PubMedID)2-s2.0-105004710040 (Scopus ID)
Projects
SNRUBC
Funder
Swedish Cancer Society, CAN 22 2021Swedish Cancer Society, CAN 2023/2807Swedish Research Council, 2021-00859Region SkåneFamiljen Hjelms stiftelse för medicinsk forskningStiftelsen Gösta Jönssons forskningsfondStiftelsen Hillevi Fries forskningsfond
Available from: 2025-06-04 Created: 2025-06-04 Last updated: 2025-06-04Bibliographically approved
Haugen Cange, H., Högmo, A., Sandström, K., Wennerberg, J., Beran, M., Söderkvist, K., . . . Farnebo, L. (2025). Radiotherapy or surgical treatment of early glottic carcinoma: a population-based study from the Swedish Head and Neck Cancer Register evaluating primary treatment outcomes for patients with T1a/T1b tumors. Cancer, 131(13), Article ID e35955.
Open this publication in new window or tab >>Radiotherapy or surgical treatment of early glottic carcinoma: a population-based study from the Swedish Head and Neck Cancer Register evaluating primary treatment outcomes for patients with T1a/T1b tumors
Show others...
2025 (English)In: Cancer, ISSN 0008-543X, E-ISSN 1097-0142, Vol. 131, no 13, article id e35955Article in journal (Refereed) Published
Abstract [en]

Background: Radiotherapy (RT) has been the treatment of choice for T1 glottic squamous cell carcinomas with curative intent; however, transoral microsurgery (MLS) has gradually taken its place. The objective of this study was to compare the outcomes of the two treatment modalities.

Methods: The Swedish Head and Neck Cancer Register contains records for 783 patients who had T1 glottic squamous cell carcinomas and planned to undergo either RT or MLS with curative intent from 2008 until 2019. These included 652 patients with T1a tumors and 125 patients with T1b tumors, resulting in 777 eligible patients.

Results: Surgical treatment led to an increased risk of recurrence compared with RT for patients who had both T1a and T1b tumors (p <.001). Forty-seven patients (6.0%) underwent laryngectomy after primary treatment. Patients with T1b tumors had a higher risk of undergoing laryngectomy (p =.01), but no significant difference in the frequency of laryngectomy was noted between the treatment modalities. Patients who had T1b tumors had a significantly worse 5-year overall survival rate compared with those who had T1a tumors, but treatment modality did not influence the overall survival rate.

Conclusions: In this population-based study of 777 patients with T1 glottic squamous cell carcinomas, no significant difference in overall survival was observed at 5 years based on treatment modality (MLS or RT). Overall survival was worse for patients with T1b carcinomas, and these patients were at an elevated risk of requiring laryngectomy. An increased risk of recurrence within 3 years was observed after surgical treatment for both T1a and T1b tumors.

Place, publisher, year, edition, pages
John Wiley & Sons, 2025
Keywords
endoscopic surgery, glottic laryngeal cancer, head and neck cancer, International Classification of Diseases code C32.0, radiotherapy, survival, T1, treatment
National Category
Cancer and Oncology Surgery
Identifiers
urn:nbn:se:umu:diva-242034 (URN)10.1002/cncr.35955 (DOI)2-s2.0-105009236297 (Scopus ID)
Available from: 2025-07-08 Created: 2025-07-08 Last updated: 2025-07-08Bibliographically approved
Häggström, C., Hagberg, O., Holmberg, L., Hosseini, A., Jerlström, T., Ströck, V., . . . Aljabery, F. (2025). Risk of upper urinary tract urothelial carcinoma after primary non-muscle-invasive urinary bladder cancer: a nationwide population-based cohort study. BJUI Compass, 6(5), Article ID e70021.
Open this publication in new window or tab >>Risk of upper urinary tract urothelial carcinoma after primary non-muscle-invasive urinary bladder cancer: a nationwide population-based cohort study
Show others...
2025 (English)In: BJUI Compass, E-ISSN 2688-4526, Vol. 6, no 5, article id e70021Article in journal (Refereed) Published
Abstract [en]

Objectives: To investigate the risk of upper urinary tract urothelial carcinoma (UTUC) in patients with non-muscle-invasive bladder cancer (NMIBC), in relation to the primary NMIBC tumour risk categories, calendar time trends and intravesical Bacillus Calmette-Guerin (BCG) treatment.

Patient and methods: All patients with primary NMIBC diagnosed 1997–2019 registered in Bladder Cancer Data base Sweden (BladderBaSe) 2.0 were included in the study. Risk of UTUC was calculated by cumulative incidence proportion using competing risk analysis. Associations with risk of UTUC by tumour stage category, calendar time, and intravesical BCG treatment was estimated by hazard ratios from multivariable Cox regression analyses.

Results: Of 36 038 NMIBC patients, 537 (1.5%) were diagnosed with UTUC during a mean time of 7 years in follow-up. The risk of UTUC within 10 years from NMIBC diagnosis was 1.7% (95% 1.6–1.9) with highest estimates for TaG3/CIS. Stage T1 and TaG3/CIS, as compared with TaG1–2 was associated to risk, with stronger associations during later calendar times. Within high-risk NMIBC patients (CIS/TaG3/T1), intravesical BCG treatment was associated with higher risk of UTUC.

Conclusions: This large study of more than 36 000 patients with NMIBC found 1.7% (95% 1.6–1.9) risk of UTUC within 10 years of diagnosis. Differences by tumour stage category indicate the need for refined studies accounting for tumour characteristics, location in the bladder and given treatment to optimise follow-up routines in NMIBC.

Place, publisher, year, edition, pages
John Wiley & Sons, 2025
Keywords
cohort study, epidemiology, register-based, surveillance, upper urinary tract urothelial carcinoma, urinary bladder cancer
National Category
Urology Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-238847 (URN)10.1002/bco2.70021 (DOI)40329969 (PubMedID)2-s2.0-105004438733 (Scopus ID)
Funder
Swedish Cancer Society, CAN 22 2021Swedish Cancer Society, CAN 2023/2807Swedish Research Council, 2021-00859Region VästerbottenFamiljen Hjelms stiftelse för medicinsk forskningStiftelsen Gösta Jönssons forskningsfondStiftelsen Hillevi Fries forskningsfond
Available from: 2025-05-20 Created: 2025-05-20 Last updated: 2025-05-20Bibliographically approved
Ullén, A., Aljabery, F., Dahlman, P., Falkman, K., Gårdmark, T., Jerlström, T., . . . Liedberg, F. (2025). Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease. Scandinavian journal of urology, 60, 76-82
Open this publication in new window or tab >>Swedish national guidelines on urothelial carcinoma: 2024 update on advanced and metastatic disease
Show others...
2025 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 60, p. 76-82Article in journal (Refereed) Published
Abstract [en]

Objective: To overview and summarise the Swedish National Guidelines on Urothelial Carcinoma 2024.

Methods: A narrative review of the updated guidelines was performed, highlighting new treatment recommendations for advanced and metastasized disease.

Results: Compared to the previous guideline version, the current update includes recommendations for standardised radiological reporting when urothelial carcinomas are detected at CT-urography (CTU), to early identify locally advanced patients and accelerate the care pathway for these patients. The Swedish guidelines apply a more structured and liberal recommendation for the use of18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with locally advanced urothelial carcinomas compared to the EAU-guidelines and recommend such examinations prior to transurethral resection. Improved outcomes for radical cystectomy in Sweden after centralised cystectomy care have led to a recommendation for performing more than six nephroureterectomies (NUs) per year for upper tract urothelial carcinomas (UTUC)-based associations with decreased use of invasive diagnostic modalities and better survival outcomes. Additionally, updated recommendations regarding adjuvant systemic therapies for muscle-invasive disease have been included. Whilst awaiting national regulatory approval for enfortumab vedotin/pembrolizumab, the present guideline version aligns with EAU-guidelines by endorsing cisplatin-gemcitabine-nivolumab as a new first-line treatment option in cisplatin-fit patients with unresectable or metastatic urothelial carcinoma.

Conclusions: The current version of the Swedish national guidelines on urothelial carcinoma introduces standardised reporting at CTU to facilitate early identification of advanced disease, includes recommendations for centralisation of NU for UTUC and updated recommendations for adjuvant systemic treatment of muscle-invasive disease and endorses cisplatin-gemcitabine-nivolumab as a new first-line treatment option for non-resectable locally advanced and metastatic disease.

Place, publisher, year, edition, pages
MJS Publishing, 2025
Keywords
advanced, Bladder cancer, guidelines, metastatic
National Category
Urology Nephrology
Identifiers
urn:nbn:se:umu:diva-237360 (URN)10.2340/sju.v60.43236 (DOI)001462624700004 ()40131172 (PubMedID)2-s2.0-105001590087 (Scopus ID)
Available from: 2025-04-23 Created: 2025-04-23 Last updated: 2025-04-23Bibliographically approved
Liedberg, F., Gårdmark, T., Hagberg, O., Aljabery, F., Ströck, V., Hosseini, A., . . . Häggström, C. (2025). Treatment related to urinary tract infections is associated with delayed diagnosis of urinary bladder cancer: a nationwide population-based study. European Urology Oncology, 8(1), 119-125
Open this publication in new window or tab >>Treatment related to urinary tract infections is associated with delayed diagnosis of urinary bladder cancer: a nationwide population-based study
Show others...
2025 (English)In: European Urology Oncology, E-ISSN 2588-9311, Vol. 8, no 1, p. 119-125Article in journal (Refereed) Published
Abstract [en]

BACKGROUND AND OBJECTIVE: It has been suggested that urinary tract infections (UTIs) are associated with delayed diagnosis of bladder cancer (BC). Our aim was to investigate prediagnostic treatments related to UTI and the relation to BC diagnostic delay, reflected by advanced disease at diagnosis.

METHODS: We used data from the BladderBaSe 2.0 with data of treatments related to UTI up to 3 yr before BC diagnosis (2008-2019) for BC patients in comparison to a matched reference population. We investigated the association between UTI treatments and more advanced disease at diagnosis in the BC cohort. We used generalized ordered logistic regression to calculate odds ratios (ORs) for more advanced disease as an ordered outcome: non-muscle-invasive BC (NMIBC), muscle-invasive BC (MIBC), and metastatic BC (MBC). KEY

FINDINGS AND LIMITATIONS: The study population included 29 921 BC patients and 149 467 matched reference subjects. The proportions of individuals receiving UTI treatment were higher in the patient groups than in the corresponding reference groups, with the greatest differences observed for the MIBC and MBC subgroups. The OR for the risk of more advanced disease (MIBC or MBC) with at least one UTI treatment versus none was 1.28 (95% confidence interval [CI] 1.19-1.37) for men and 1.42 (95 % CI 1.27-1.58) for women. The association to risk of more advanced disease increased with the number of UTI treatments for both sexes.

CONCLUSIONS AND CLINICAL IMPLICATIONS: Further studies on the effects of treatments related to UTI in combination with other factors are needed to identify reasons for possible delays in the BC diagnostic pathway.

PATIENT SUMMARY: We found that for patients with bladder cancer, previous antibiotic treatment for a urinary tract infection was linked to more advanced disease at diagnosis. Further studies are needed to identify reasons for possible delays in the diagnosis of bladder cancer.

Place, publisher, year, edition, pages
Elsevier, 2025
Keywords
Bladder cancer, Diagnostic delay, Register-based study, Urinary tract infection
National Category
Urology Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-236190 (URN)10.1016/j.euo.2024.07.008 (DOI)001426105100001 ()39143001 (PubMedID)2-s2.0-85218503178 (Scopus ID)
Projects
Swedish National Urinary Bladder Cancer Register (SNRUBC)
Funder
Swedish Cancer Society, CAN 2023/2807Swedish Cancer Society, CAN 22 2021Swedish Research Council, 2021-00859Familjen Hjelms stiftelse för medicinsk forskningStiftelsen Gösta Jönssons forskningsfondLions Cancerforskningsfond i NorrStiftelsen Hillevi Fries forskningsfond
Note

Available from: 2025-03-17 Created: 2025-03-17 Last updated: 2025-03-17Bibliographically approved
Zarei, M., Wallstén, E., Grefve, J., Söderkvist, K., Gunnlaugsson, A., Sandgren, K., . . . Nyholm, T. (2024). Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer. Acta Oncologica, 63, 503-510
Open this publication in new window or tab >>Accuracy of gross tumour volume delineation with [68Ga]-PSMA-PET compared to histopathology for high-risk prostate cancer
Show others...
2024 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 63, p. 503-510Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The delineation of intraprostatic lesions is vital for correct delivery of focal radiotherapy boost in patients with prostate cancer (PC). Errors in the delineation could translate into reduced tumour control and potentially increase the side effects. The purpose of this study is to compare PET-based delineation methods with histopathology.

MATERIALS AND METHODS: The study population consisted of 15 patients with confirmed high-risk PC intended for prostatectomy. [68Ga]-PSMA-PET/MR was performed prior to surgery. Prostate lesions identified in histopathology were transferred to the in vivo [68Ga]-PSMA-PET/MR coordinate system. Four radiation oncologists manually delineated intraprostatic lesions based on PET data. Various semi-automatic segmentation methods were employed, including absolute and relative thresholds, adaptive threshold, and multi-level Otsu threshold.

RESULTS: The gross tumour volumes (GTVs) delineated by the oncologists showed a moderate level of interobserver agreement with Dice similarity coefficient (DSC) of 0.68. In comparison with histopathology, manual delineations exhibited the highest median DSC and the lowest false discovery rate (FDR) among all approaches. Among semi-automatic approaches, GTVs generated using standardized uptake value (SUV) thresholds above 4 (SUV > 4) demonstrated the highest median DSC (0.41), with 0.51 median lesion coverage ratio, FDR of 0.66 and the 95th percentile of the Hausdorff distance (HD95%) of 8.22 mm.

INTERPRETATION: Manual delineations showed a moderate level of interobserver agreement. Compared to histopathology, manual delineations and SUV > 4 exhibited the highest DSC and the lowest HD95% values. The methods that resulted in a high lesion coverage were associated with a large overestimation of the size of the lesions.

Place, publisher, year, edition, pages
MJS Publishing, Medical Journals Sweden, 2024
National Category
Cancer and Oncology Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-227761 (URN)10.2340/1651-226X.2024.39041 (DOI)001258458500005 ()38912830 (PubMedID)2-s2.0-85197008510 (Scopus ID)
Funder
Cancerforskningsfonden i NorrlandSwedish Cancer SocietyRegion Västerbotten
Available from: 2024-07-09 Created: 2024-07-09 Last updated: 2024-07-09Bibliographically approved
Strandberg, S., Jonsson, J., Zarei, M., Aglund, K., Blomqvist, L. & Söderkvist, K. (2024). Baseline and early response 2-[18F]FDG-PET/MRI for prediction of radiotherapy outcome in uterine cervical squamous cell carcinoma: a prospective single-center observational cohort study. EJNMMI Reports, 8(1), Article ID 5.
Open this publication in new window or tab >>Baseline and early response 2-[18F]FDG-PET/MRI for prediction of radiotherapy outcome in uterine cervical squamous cell carcinoma: a prospective single-center observational cohort study
Show others...
2024 (English)In: EJNMMI Reports, E-ISSN 3005-074X, Vol. 8, no 1, article id 5Article in journal (Refereed) Published
Abstract [en]

Background: Should early response imaging predict tumor response to therapy, personalized treatment adaptations could be feasible to improve outcome or reduce the risk of adverse events. This prospective single-center observational study on 2-fluorine-18-fluoro-deoxy-glucose (2-[18F]FDG) positron-emission tomography/magnetic resonance imaging (PET/MRI) features aims to investigate the association between semantic 2-[18F]FDG-PET/MRI imaging parameters and outcome prediction in uterine cervical squamous cell carcinoma (CSCC) treated with radiotherapy.

Results: Eleven study participants with previously untreated CSCC were examined with 2-[18F]FDG-PET/MRI at baseline and approximately one week after start of curative radiotherapy. All study participants had at least 24 months clinical follow-up. Two patients relapsed during the follow-up period. Reduced tumor size according to visual assessment was present in 9/11 participants (median change in sum of largest diameters (SLD) − 10.4%; range − 2.5 to − 24.6%). The size reduction was less pronounced in the relapse group compared to the no relapse group, with median change in SLD − 4.9%, versus − 10.4%. None of the reductions qualified as significantly reduced or increased in size according to RECIST 1.1., hence all participants were at this stage classified as non-responders/stable disease. Median baseline functional tumor volume (FTV) for the relapse group was 126 cm3, while for the no relapse group 9.3 cm3. Median delta FTV in the relapse group was 50.7 cm3, representing an actual increase in metabolically active volume, while median delta FTV in the no relapse group was − 2.0 cm3. Median delta apparent diffusion coefficient (ADC) was lower in the relapse group versus the no relapse group (− 3.5 mm2/s vs. 71 mm2/s).

Conclusions: Early response assessment with 2-[18F]FDG-PET/MRI identified potentially predictive functional imaging biomarkers for prediction of radiotherapy outcome in CSCC, that could not be recognized with tumor measurements according to RECIST 1.1. These biomarkers (delta FTV and delta ADC) should be further evaluated.

Place, publisher, year, edition, pages
Springer Nature, 2024
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-222628 (URN)10.1186/s41824-024-00188-7 (DOI)001172414800001 ()38748271 (PubMedID)2-s2.0-85196315772 (Scopus ID)
Funder
Swedish Cancer SocietyUmeå UniversityRegion Västerbotten
Available from: 2024-03-22 Created: 2024-03-22 Last updated: 2025-01-13Bibliographically approved
Holmberg, L., Skogmar, S., Garmo, H., Hagberg, O., Häggström, C., Gårdmark, T., . . . Liedberg, F. (2024). Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations. BJU International, 134(2), 229-238
Open this publication in new window or tab >>Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations
Show others...
2024 (English)In: BJU International, ISSN 1464-4096, E-ISSN 1464-410X, Vol. 134, no 2, p. 229-238Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: To investigate the cumulative incidence proportion of disseminated or local Bacillus Calmette-Guérin (BCG) infections after adjuvant BCG instillations in patients with non-muscle-invasive bladder cancer (NMIBC).

PATIENTS AND METHODS: We analysed the timing and occurrence of BCG infections and absolute and relative risk in relation to patient characteristics available in the Swedish nationwide database 'BladderBaSe 2.0'. The cumulative incidence proportion of a BCG infection was indicated by a reported diagnosis of tuberculosis (TB) in the patient registry or filing a prescription for tuberculostatic drugs.

RESULTS: The cumulative incidence proportion was 1.1% at the 5-year follow-up in 5033 patients exposed to adjuvant BCG instillations. The incidence rate was highest during the first 2 years after start of BCG instillations. Women had a lower risk than men (hazard ratio 0.23, 95% confidence interval 0.07-0.74). Age and calendar time at diagnosis, comorbidity, tumour risk group, previous medication with corticosteroids, immunosuppressive drugs, or time between transurethral resection of the bladder tumour and commencing the adjuvant BCG instillation were not associated with risk.

CONCLUSIONS: These data further supports that the overall risk of a BCG infection after BCG-instillation treatment for NMIBC is low. The great majority of infections occur in the first 2 years, calling for an awareness of the diverse symptoms of BCG infection during this period. We provide evidence for male sex as a risk factor; however, the statistical precision is low and with a risk of selection bias, making it difficult to rule out the other suggested risk factors without further studies with different approaches.

Place, publisher, year, edition, pages
John Wiley & Sons, 2024
Keywords
BCG instillations, cumulative incidence proportion, local or systemic BCG infections, non-muscle-invasive bladder cancer, risk factors
National Category
Clinical Medicine
Identifiers
urn:nbn:se:umu:diva-221629 (URN)10.1111/bju.16303 (DOI)001172824600001 ()38403809 (PubMedID)2-s2.0-85186546298 (Scopus ID)
Funder
Swedish Cancer Society, CAN 2022/1971Swedish Cancer Society, CAN 2023/2807Swedish Research Council, 2021-00859
Available from: 2024-02-29 Created: 2024-02-29 Last updated: 2025-02-18Bibliographically approved
Liedberg, F., Hagberg, O., Aljabery, F., Gårdmark, T., Jahnson, S., Jerlström, T., . . . Bobjer, J. (2024). Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey. Scandinavian journal of urology, 59, 19-25
Open this publication in new window or tab >>Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey
Show others...
2024 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 59, p. 19-25Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To report national data on diagnostics and treatment of upper tract urothelial carcinoma (UTUC) from the Swedish National Registry of Urinary Bladder Cancer (SNRUBC).

PATIENTS AND METHODS: Data from 2015 to 2021 were retrieved, and descriptive analyses were performed regarding incidence, diagnostic modalities, preoperative tumor staging, quality indicators for treatment including the use of standardized care pathways (SCP) and multidisciplinary tumor boards (MDTB). Time trends were explored for the study period.

RESULTS: Registrations included 1,213 patients with renal pelvic cancer and 911 patients with ureteric cancer with a median age of 74 (interquartile range [IQR] 70-77) and 75 (IQR 71-78) years, respectively. Incidence rates of UTUC were stable, as were proportions of curative treatment intent. Median number of days from referral to treatment was 76 (IQR 57-99) and 90 (IQR 72-118) days, respectively, for tumors of the renal pelvis and ureter, which remained unchanged after introduction of SCP in 2016. Noticeable trends included stable use of kidney-sparing surgery and increased use of MDTB. For radical nephroureterectomy (RNU), robot-assisted technique usage increased even for non-organ-confined tumors (cT3-4) and in one out of three patients undergoing RNU a bladder cuff excision was not registered.

CONCLUSIONS: The population-based SNRUBC with high coverage contributes to the knowledge about UTUC with granular and generalizable data. The present study reveals a high proportion of patients not subjected to curatively intended treatment and suggests unmet needs to shorten lead times to treatment and use of bladder cuff excision when performing radical surgery for UTUC in Sweden.

Keywords
Upper tract urothelial carcinoma, Epidemiology, Ureteric cancer, Renal pelvic cancer, Nephroureterectomy
National Category
Clinical Medicine
Identifiers
urn:nbn:se:umu:diva-220006 (URN)10.2340/sju.v59.16281 (DOI)001278332500003 ()38226846 (PubMedID)2-s2.0-85182543992 (Scopus ID)
Funder
Swedish Cancer Society, CAN 2020/0709Swedish Research Council, 2021-00859Region Skåne, EGSKANE-622351Stiftelsen Gösta Jönssons forskningsfondStiftelsen Hillevi Fries forskningsfond
Available from: 2024-01-31 Created: 2024-01-31 Last updated: 2025-04-24Bibliographically approved
Grefve, J., Söderkvist, K., Gunnlaugsson, A., Sandgren, K., Jonsson, J., Keeratijarut Lindberg, A., . . . Nyholm, T. (2024). Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging. Physics and Imaging in Radiation Oncology, 31, Article ID 100633.
Open this publication in new window or tab >>Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging
Show others...
2024 (English)In: Physics and Imaging in Radiation Oncology, E-ISSN 2405-6316, Vol. 31, article id 100633Article in journal (Refereed) Published
Abstract [en]

Background and purpose: Dose escalation in external radiotherapy of prostate cancer shows promising results in terms of biochemical disease-free survival. Boost volume delineation guidelines are sparse which may cause high interobserver variability. The aim of this research was to characterize gross tumor volume (GTV) delineations based on multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen-positron emission tomography (PSMA-PET) in relation to histopathology-validated Gleason grade 4 and 5 regions.

Material and methods: The study participants were examined with [68Ga]PSMA-PET/mpMRI prior to radical prostatectomy. Four radiation oncologists delineated GTVs in 15 study participants, on four different image types; T2-weighted (T2w), diffusion weighted imaging (DWI), dynamic contrast enhanced (DCE) and PSMA-PET scans separately. The simultaneous truth and performance level estimation (STAPLE) algorithm was used to generate combined GTVs. GTVs were subsequently compared to histopathology. We analysed how Dice similarity coefficient (DSC) and lesion coverage are affected by using single versus multiple image types as well as by adding a clinical target volume (CTV) margin.

Results: Median DSC (STAPLE) for different GTVs varied between 0.33 and 0.52. GTVPSMA-PET/mpMRI generated the highest median lesion coverage at 0.66. Combining different image types achieved similar lesion coverage as adding a CTV margin to contours from a single image type, while reducing non-malignant tissue inclusion within the target volume.

Conclusion: The combined use of mpMRI or PSMA-PET/mpMRI shows promise, achieving higher DSC and lesion coverage while minimizing non-malignant tissue inclusion, in comparison to the use of a single image type with an added CTV margin.

Place, publisher, year, edition, pages
Elsevier, 2024
National Category
Radiology, Nuclear Medicine and Medical Imaging Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-229329 (URN)10.1016/j.phro.2024.100633 (DOI)001313678300001 ()2-s2.0-85202586079 (Scopus ID)
Funder
Swedish Cancer SocietyCancerforskningsfonden i NorrlandProstatacancerförbundetRegion Västerbotten
Available from: 2024-09-13 Created: 2024-09-13 Last updated: 2025-04-24Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-3683-3763

Search in DiVA

Show all publications